下一代肿瘤不可知靶点即将出现
Next-generation tumor-agnostic targets on the horizon.
肿瘤不可知药物开发将肿瘤学重新聚焦于共享的分子依赖性而非组织来源,从而能够针对跨肿瘤的罕见可操作驱动因素进行高效开发。
英文原题:Tumor-Derived Microvesicles Promote Kidney Regeneration and Cytoprotective Immunomodulation.
Tumor-Derived Microvesicles Promote Kidney Regeneration and Cytoprotective Immunomodulation.
这些发现提示,T-MVs 与 MSC-MVs 相似,具有促进肾组织再生的普遍能力,并可发挥抗炎免疫调节作用。
背景:本比较研究评估细胞外肿瘤来源微囊泡(MV)促进肾脏再生的潜力。方法:从L929肉瘤、LLC肺癌、B16黑色素瘤细胞及间充质干细胞(MSC)中收集MV,并在小鼠慢性肾损伤(CKI)实验模型中评估其再生作用。结果:肿瘤来源MV(T-MV)和MSC来源MV(MSC-MV)均显著改善肾功能和组织学结构。具体而言,MV治疗后肾髓质中三分之一区域集合管高度恢复至正常水平。T-MV和MSC-MV均降低CKI小鼠肾脏细胞浸润物及脾脏中促炎性CD4+CD44+ T细胞的比例。此外,MV治疗增加脾脏中天然CD4+CD25+FoxP3+调节性T细胞的数量,提示其具有免疫调节作用。结论:这些发现表明,与MSC来源MV相似,T-MV具有广泛促进肾组织再生及发挥抗炎免疫调节作用的能力。
Background: A comparative study was conducted to evaluate the potential of extracellular, tumor-derived microvesicles (MVs)s in promoting kidney regeneration. Methods: MVs were collected from L929 sarcoma, LLC, and B16 melanoma cells, and mesenchymal stem cells (MSCs). The regenerative activity of MVs was evaluated in an experimental murine model of chronic kidney injury (CKI). Results: Both tumor-derived MVs (T-MVs) and MSC-derived MVs (MSC-MVs) significantly improved kidney function and histological structure. Specifically, the height of collecting tubules in the middle third of the renal medulla returned to normal levels following MV treatment. Both T-MVs and MSC-MVs reduced the proportion of pro-inflammatory CD4+CD44+ T cells in renal cell infiltrates and spleens of CKI mice. Furthermore, treatment with these MVs increased the number of natural CD4+CD25+FoxP3+ regulatory T cells in the spleen, indicating their immunomodulatory effects. Conclusions: These findings suggest that T-MVs, similar to MSC-MVs, possess a universal capacity to promote kidney tissue regeneration and exert anti-inflammatory immunomodulatory effects.
MEMBER ACCOUNT
登录成功会直接打开下一页。